Prices have been dramatically increasing for many older, off-patent drugs, some of which are considered “essential” by the World Health Organization. Some price hikes have made potentially life-saving therapies unavailable to disadvantaged patients in the United States.
No takes yet. Share an insight, caveat, or question.
Alpern et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: